Physician profile
Michael Valastro
NPI 1619081312
$20,422.48
in general payments reported to CMS, 2019-2025
16 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $1,759 · 2021: $1,513 · 2022: $530 · 2023: $2,768 · 2024: $300 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,276 · Food and Beverage: $2,225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,276.29 |
| Food and Beverage | $2,224.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $10,195.49 | 2019-2020 | |
| Smith+Nephew, INC. | $4,833.39 | 2019-2025 | Journey, Ri Hip Navigation, Real Intelligence |
| Medinc of Texas | $2,275.00 | 2019-2023 | |
| Arthrex, INC. | $1,941.37 | 2019-2020 | |
| Stryker Corporation | $267.72 | 2020-2022 | |
| Orthalign INC | $225.37 | 2021-2024 | Orthalign Plus |
| Heron Therapeutics, INC. | $191.61 | 2021-2023 | Zynrelef |
| Radius Health, INC. | $122.91 | 2019 | |
| Bioventus LLC | $105.11 | 2019-2025 | Xcell |
| Pacira Pharmaceuticals Incorporated | $65.28 | 2023-2025 | Iovera, Zilretta, Exparel |
| Ferring Pharmaceuticals INC. | $60.26 | 2020-2022 | |
| Abbott Laboratories | $56.59 | 2019 | |
| Kerecis Limited | $22.68 | 2019 | |
| Depuy Synthes Sales INC. | $22.25 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.33 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $18.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Valastro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.